Abscisic acid and low-dose TZD combination therapy for type 2
This patent covers a drug combination therapy that pairs abscisic acid (ABA), a naturally occurring plant hormone also found in mammals, with thiazolidinediones (TZDs), a class of approved diabetes medications. Together, they activate PPAR-gamma, a protein that regulates fat cell development and insulin sensitivity, more effectively than either compound alone. The synergy allows for lower doses of TZDs, which carry known side effects including weight gain, fluid retention, and cardiovascular risk. The result is a combination that targets insulin resistance, obesity-related inflammation, and related metabolic disorders with an improved safety profile.
What you could build
A combination pharmaceutical or nutraceutical product pairing abscisic acid with a reduced-dose TZD for type 2 diabetes or metabolic syndrome patients; buyers would be specialty pharma companies or nutraceutical brands targeting the diabetes management market.
Who in Virginia should care
Virginia-based pharmaceutical companies, biotech startups in the Northern Virginia/DC corridor, or nutraceutical brands in the Mid-Atlantic region focused on metabolic health would be natural partners or licensees.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Josep BASSAGANYA-RIERA, Amir J. GURI, Raquel HONTECILLAS
- Granted
- September 1, 2015
- Status
- Granted patent
- Patent number
- 9119881
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.